Following the successful presentation last month in London at the “Advanced Therapies 2024 Conference”  which discussed Secretomix®’s ability to improve gut and lung structure through its modulation of inflammatory pathways, Micregen are pleased to announce their Head of Development Dr. Robert Mitchell has been invited  to present in May at the “Discover, Innovate and Understand” ISEV2024  meeting in Melbourne, Australia . This time, on a preliminary study into the ability of Secretomix® to increase key neural cell populations in a model of Alzheimer’s Disease which has been accepted by the International Society for Extracellular Vesicles (ISEV).

This event attracts a global audience of researchers, as well as other industrial, academic and regulatory experts, providing an excellent opportunity for further validation as we progress with the development of our first therapeutic candidate.

#ISEV2024, #Micregen